Fast-progressing felty syndrome following abrupt methotrexate withdrawal

Felty syndrome (FS), characterised by splenomegaly and neutropenia, develops after a protracted course of erosive rheumatoid arthritis. In addition to deformities of the joints, FS can cause a variety of extra-articular symptoms, including vasculitis, skin rashes, and lymphadenopathy. Moreover, FS has been connected to non-cirrhotic portal hypertension, which might result in variceal bleeding. FS is usually treated with disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate. Here, we report a case of rapidly developing FS accompanied by a significant relapse in neutropenia that happened only a few weeks after methotrexate and other available DMARDs were withdrawn. Indicative of ecthyma gangrenosum, the patient developed a fever and a gangrenous ulcer that was resistant to many medications. In one case, the patient also had hepatosplenomegaly and portal hypertension. Since the patient was unable to receive or could not afford DMARDs, the only treatments utilised in this case were antibiotics and symptomatic treatments. However, the patient's condition did not improve. This case illustrates why DMARDs are thought to be an essential part in treating infections caused by FS neutropenia. Patients with Felty Syndrome should take DMARDs consistently to avoid a relapse of their condition.

People who are suspected of having Felty syndrome should be started on DMARDs as soon as the diagnosis is made, and it is highly recommended that they follow these prescriptions. Clinical advice should include possible alternatives to current therapies for countries with limited resources.¹

A brief glance at three cases followed up with a diagnosis of felty syndrome

As of right now, Felty syndrome (FS) has no established course of treatment. Nonetheless, several treatment combinations are tried and the progress of the improvement of the ailments is observed. A paper describes three cases with FS that improved with different treatment plans. 

1. In Case 1, a 52-year-old male patient initially received methotrexate treatment. Nevertheless, his treatment was switched to granulocyte colony-stimulating factor (G-CSF) and cyclosporine when his neutropenia got worse. The patient's steroid dosage was increased, and he needed to take monthly doses of G-CSF for more than six months. His neutropenia improved after cyclosporine, methotrexate, and hydroxychloroquine combination treatment
2. In Case 2, a 78-year-old female patient started using leflunomide, hydroxychloroquine, and 60 mg of methylprednisolone
3. In Case 3, a 69-year-old female patient first got 32 mg of methylprednisolone and G-CSF before being prescribed cyclosporine

Both patients' neutropenia subsided, and their health was restored to normal after two months.

Treatment for Felty Syndrome has been attempted several times; G-CSF with disease-modifying antirheumatic medications has proven to be effective. Remember that people might appear primarily with symptoms of infections or hematologic problems.

In conclusion,  Felty Syndrome has been treated with a range of therapeutic modalities. DMARDs and G-CSF can be used together or individually with successful results. It's crucial to keep in mind that, in rare cases, certain FS patients may have symptoms that are mostly haematological and infectious.²

Severe resorption of alveolar bone in felty syndrome

When poor oral hygiene and pancytopenia are combined, severe periodontitis may develop. Strong coordination between the dental and medical teams is required when two conditions coexist in order to prevent potentially deadly situations and enhance the patient's quality of life. We used a pre- and postoperative antibiotic treatment strategy to control infection in this case of FS with neutropenia. Despite its relative rarity, this illness should be taken into account as a differential diagnosis in clinical practice while treating patients with leukopenia and neutropenia. Additionally, pancytopenia can be caused by a number of factors, therefore, it's critical to collaborate closely with other relevant departments to reduce complications during invasive dental procedures. However, further case studies and evidence supporting this theory are needed. Even if a patient has severe chronic periodontitis and FS, they can still benefit from full dental therapy, which involves tooth preservation, extraction surgery, and thorough prosthetic treatment. This can be accomplished by assisting the patient in adopting a healthier lifestyle and managing the underlying illness in collaboration with a hematologist.³

Treatment with granulocyte colony-stimulating factor is refractory to non-articular felty syndrome

Rheumatoid arthritis (RA) patients may develop Felty syndrome (FS), which often manifests as a triad of erosive arthritis, splenomegaly, and neutropenia. It is uncommon for RA to develop into FS or for splenomegaly and neutropenia to be the primary symptoms.⁴

In one case, the patient responded to filgrastim 480 mcg with only modest improvements in WBC and ANC. Once oral prednisone 30 mg twice a day was begun, as the patient did not present with an active infection.⁴

The WBC count showed a discernible improvement. Subsequently, filgrastim was discontinued, and the patient had prednisone therapy until their discharge (Table 1). During the patient's hospital stay, methotrexate was not begun because the results of the anti-CCP antibody test were not originally made public.⁴

This patient's neutropenia improved following a five-day course of G-CSF medication. However, it was only temporary, since the neutropenia worsened two weeks after the medication was discontinued. The response was far worse at the second admission. In the absence of an articular ailment, the diagnosis of FS may be challenging, thus, medical practitioners should be very suspicious. Treatment for FS-related neutropenia may involve hematopoietic growth factor therapy, such as filgrastim; if infection is not continuing, glucocorticoid medication is a preferable option.⁴

Treating an elderly patient with advanced rheumatoid arthritis and exudative pleurisy associated with felty syndrome

Extra-articular signs of advanced rheumatoid arthritis (RA) include pleurisy, lung fibrosis, and small- and medium-sized vasculitis. The illness has a notable and refractory clinical course. Treatment of advanced RA presenting with several extra-articular symptoms is difficult.⁵

When examining older patients with RV accompanied by pleurisy and Felty syndrome thoroughly and considering the quick escalation of symptoms, it is essential to initiate steroids and immunosuppressive medications.⁵

It is possible to differentiate between infections caused by immunosuppression and rheumatic issues emerging from severe RA based on the clinical history. Since Felty syndrome is not always easily diagnosed, collaborative decision-making is crucial to the creation and execution of comprehensive treatment plans for senior patients with rheumatic illnesses.⁵

Treating older patients with serious issues related to RA is challenging. Differentiating immunosuppressive infections from rheumatic effects from severe RA requires a detailed strategy, depending on the patient's level of immunosuppression. Since the diagnosis of Felty syndrome can be challenging, coordinated decision-making is essential to enhancing the comprehensive treatment of older people with rheumatic illnesses.⁵

The management of felty syndrome in rheumatoid arthritis with abatacept

An 81-year-old man who had rheumatoid arthritis for 22 years was studied in a case where he experienced pancytopenia and neutropenia for a month. Splenomegaly was revealed by an abdominal ultrasonography. After a bone marrow biopsy excluded big granular lymphocytic leukaemia, Felty Syndrome was identified. He was given the maximum tolerated dose of methotrexate (15 mg once weekly) for two months, but there was no improvement in his absolute neutrophil count. The patient saw improvements in their haemoglobin, leukocyte, and platelet counts in addition to an increase in absolute neutrophil counts from 0.2 to 2.4 K/µl every four weeks when they received 1000 mg of abatacept intravenously. In this instance, the Abatacept therapy choice proved to be effective.⁶

Treatment of felty's syndrome neutropenia

Patients get better outcomes after receiving medicines, in contrast to those who are currently infected as well as those who are neutropenic; yet, it's plausible that these patients would have thrived in the absence of support. Therefore, it is advisable not to treat these individuals unless their neutropenia is quite severe. If a prompt treatment for neutropenia is necessary, G-CSF or GM-CSF are appropriate first replacement. Some people might not be able to tolerate long-term growth elements due to the necessity for subcutaneous drug administration. The other option can be about methotrexate use. Low-dose methotrexate can be tried if the growth factors are unsuccessful or poorly tolerated; if a response is not shown after 1-2 months, splenectomy should be taken into consideration. Accessible data suggest that most patients will display a hematologic reaction following splenectomy and experience a decrease in infections.⁷

Felty's syndrome: extended monitoring following auranofin treatment

None of the patients had any infections, both during the auranofin therapy and the follow-up exam period. When the patient stopped taking medicine because of diarrhoea, auranofin first helped with clinical symptoms, normalised white blood cell counts, and improved trophic ulcers in the lower limbs. Parenteral gold, or sodium aurothiomalate, was administered to this patient; however, the medication was discontinued as soon as the patient showed signs of a clinical relapse of the illness along with a decrease in white blood cell count.⁸

A brief description of auranofin's pharmacological characteristics and potential use in the treatment of rheumatoid arthritis

It has been demonstrated that auranofin outperforms a placebo in almost every assessment criterion for rheumatoid arthritis patients. Auranofin has typically been demonstrated to be substantially less harmful than sodium aurothiomalate in rheumatoid arthritis research, but it has also been shown to be less effective.⁹

Methotrexate treatment for felty's syndrome

Preliminary evidence, as per Oxford research, bolsters the safety and effectiveness of low-dose methotrexate treatment as a therapeutic substitute.¹⁰ Thus, for several treatment options, Methotrexate can be considered as a safe option even though Felty Syndrome does not have a definite treatment method. 

Treatment of felty's syndrome via the use of etanercept

Finally, it's critical to consider how ineffective etanercept is at treating FS. This notion is supported by a recent study that looked at the ineffectiveness of etanercept on FS non-patients with RA and eventual amyloidosis.¹¹  As of right now, we advise people with Felty Syndrome to use etanercept cautiously.¹²

Summary

Felty Syndrome (FS), a rare complication of long-standing rheumatoid arthritis (RA), is marked by neutropenia, splenomegaly, and erosive arthritis. Its management is challenging due to varied clinical presentations, including hematological and infectious complications. The mainstay of FS treatment involves disease-modifying anti-rheumatic drugs (DMARDs), particularly methotrexate, which helps control neutropenia and RA progression. Abrupt withdrawal of DMARDs may trigger rapid relapse and severe infections.

In patients unresponsive to methotrexate or unable to tolerate it, alternatives like cyclosporine, hydroxychloroquine, leflunomide, and glucocorticoids have shown efficacy. Granulocyte colony-stimulating factor (G-CSF) is effective in boosting neutrophil counts but often provides only temporary relief. Splenectomy is considered in refractory cases. Biologic agents like abatacept have shown promise, while etanercept has been largely ineffective in FS cases.

Oral health complications, like severe periodontitis due to pancytopenia, necessitate multidisciplinary care. Early and consistent treatment with DMARDs is crucial, and resource-limited settings require tailored approaches to therapy. Overall, a combination of immunosuppressants, hematopoietic support, and close monitoring is essential in managing FS.